Considering its high performance and accuracy in the classification of variants in BRCA1 and BRCA2, we believe that it could provide sufficient evidence for the localization of pathogenicity in these specific genes and thus contribute to the prognosis and/or diagnosis of breast or ovarian cancer. The gene discussed is BRCA2; the disease is ovarian carcinoma.